[Transabdominal cervico-isthmic cerclage: 13 cases at Rouen University Hospital]

OBJECTIVE

The aim of this study was to describe our experience with cervico-isthmic cerclage by abdominal approach and to assess this efficacy.

PATIENTS AND METHODS

A retrospective analysis of 13 transabdominal cerclages (eight by laparotomy and five by laparoscopy), seven cases performed before pregnancy and six cases between 12 and 14 weeks of gestation, between 2004 and 2009. We analyzed the previous obstetric accidents, the etiology of cervical incompetence and the patient outcome after cerclage.

RESULTS

Median age of the patients was 35 years [27-42 years]. Patients had an average of pregnancy 4,2 [1-7], with 3,3 previous fetal losses or preterm delivery. Eighty percent had a prior failed transvaginal cerclage. The mean operative time of laparotomic cerclage was 100 minutes and 94 minutes by laparoscopy, with a mean hospitalization time respectively of seven and 2,5 days. No operative complication was reported. Eleven women were pregnant after cervico-isthmic cerclage: nine deliveries by caesarean section at term, and two preterm births between 34 and 37 weeks of gestation. Two patients are looking for being pregnant and one of those is currently doing a procedure of IVF.

DISCUSSION AND CONCLUSION

Transabdominal cervico-isthmic cerclage is an alternative technique for the management of cervical incompetence after failed vaginal cerclage. Our data indicated that the cervico-isthmic cerclage placed laparoscopically compares favorably with the laparotomy approach in regard to operative technique and risk of complications.

ER Status and Immune Module Are Central Determinants of HER2 Amplified Infiltrative Breast Carcinoma Prognosis and Pathologic Complete Response

IntroductionGene expression profiling of invasive breast cancer has resulted in highlighting three main categories of breast cancer [luminal, basal, HER2] with very specific features. It has been shown that these subtypes differ in their response to neaoadjuvant systemic treatment, axillary lymph node involvement, metastasis pattern and time to metastasis. The aim of this study was to focus on gene-expression profile analysis of HER2 positive breast carcinoma to assess how the molecular subtype classification applies to the HER2+ve samples; whether subgroups of patients that have different prognosis can be identified and how subgroups can be identified that differ with respect to the likelihood to achieve pathologic complete response (pCR) after neoadjuvant systemic treatment?Materials and MethodWe selected breast carcinomas reported to have a HER2+ve status (IHC and CISH) from patients treated between January 1990 and December 2006 at the Netherlands Cancer Institute. 113 tumor samples were hybridized on the Human Genome Oligo Set Version 3.0 arrays. We identified 205 HER2+ve samples from 4 public microarrays datasets and 33 HER2+ve samples from one public neoadjuvant systemic treatment microarrays dataset.ResultsWe applied the molecular subtype classification to the whole datasets and found major classification instability. 43.3% of the HER2+ve samples were classified as “HER2 subtype”, 26% as “basal-like subtype”, and 21.9% as “luminal-like subtype”. The molecular subtype classification was not correlated to prognosis. Of the prognostic variables tested, only ER status was to the development of distant metastasis (IHC, HR=0.53 [0.36-0.77], p=0.0009). We identified a set of 109 ReporterID's highly enriched in gene ontology annotations link to the Immune Response and correlated to the prognosis of HER2+ve breast carcinoma (Inactivated Immune Module, HR=4.21 [1.94-9.17], logrank pvalue=8.1E-05). The Immune Module Signature was associated with prognosis of the HER2+ve samples in both ER positive and ER negative breast cancer. We validated this Immune Module signature combined with ER status on 205 independent samples.We applied the same classification tree to 33 samples from patients who were assessed for response to neo-adjuvant systemic chemotherapy (Anthracyclin-based) and showed an association between the Immune Module Signature combined with ER status and pCR rate (ER+ve Inactivated Immune Module 12.5% pCR, ER-ve Activated Immune Module 70% pCR, pvalue=0.1).ConclusionWe have shown that HER2+ve breast cancer samples often are not classified as HER2-like by gene expression profiling and that ER (IHC) status determines two major subgroups. We provide new evidence that an immune response relate gene expression classifier has prognostic impact in HER2+ve breast cancer; and that this classifier is potentially correlated to the pCR rate after neoadjuvant systemic treatment in HER2+ve breast cancer.

Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4037.

Metastatic spread of gynaecological neoplasms to the adrenal gland: case reports with a review of the literature

Metastatic involvement of the adrenal glands due to gynaecological neoplasms is a relatively rare condition. The aim of our study was to present four cases of metastases to the adrenal gland due to endometrial adenocarcinoma, ovarian and cervical cancer. These cases are correlated with a review of the literature. CT scan and MRI have been previously used in an attempt to define the nature of the adrenal mass but this approach is of limited value in diagnosis. Image-guided pathological confirmation of an adrenal lesion may significantly change the staging or management of the primary neoplasm. The authors suggest that isolated adrenal metastasis should be routinely considered for surgical management.

[Acute orthostatic intracranial hypotension]

The case of a young female with an acute idiopathic low cerebrospinal fluid pressure is presented. Clinical-imaging manifestations were typical and two consecutive blood patches resulted in a complete and durable resolution of the symptomatology. We present a review of the various investigation and therapeutic techniques.